Batista J Emilio, Palacio Andrés, Torrubia Rafael, Hernández Carlos, Vicente José, Resel Luis
Urology Service, Fundación Puigvert, Barcelona, Spain.
Arch Esp Urol. 2002 Jan-Feb;55(1):97-105.
To investigate the influence of tamsulosin treatment on the severity of lower urinary tract symptoms (LUTS) and the impact on quality of life (QoL), including daily life activities and mental well being, in real life practice in Spain.
2740 LUTS patients aged 45-75 years who visited a urologist office in Spain received tamsulosin 0.4 mg o.d.. At baseline, after 3 months and after 6 months of treatment a questionnaire was completed by the urologist and the patient. The urologist estimated some aspects of the patient's QoL related to his LUTS. The International Prostate Symptom Score (I-PSS) was used to assess the severity of LUTS, while the BPH-Specific Interference with Activities (BSIA) and the Total Mental Health Rate assessed the impact on daily life activities and psychological well being respectively.
After 3 months of treatment tamsulosin significantly improved the mean total I-PSS compared to baseline. After 6 months, the mean total I-PSS was reduced by 11.0 points from a baseline score of 20.3 (> 50% reduction). Tamsulosin also significantly improved the mean total BSIA score and the mean Total Mental Health Rate. These observations were confirmed by the urologists' assessment of the patient's condition: an increase of more than 50% of patients with no or mild voiding and filling LUTS and an increase of 45% of patients with no or only a small interference of their LUTS with daily life activities. The withdrawal rate due to adverse reactions was 2.4%.
This study shows that tamsulosin improves LUTS and their impact on the patient's QoL and daily life activities, in the opinion of both the patients and the urologists.
在西班牙的实际临床实践中,研究坦索罗辛治疗对下尿路症状(LUTS)严重程度的影响以及对生活质量(QoL)的影响,包括日常生活活动和心理健康。
2740名年龄在45 - 75岁之间前往西班牙泌尿外科诊所就诊的LUTS患者接受了每日一次0.4毫克坦索罗辛治疗。在基线、治疗3个月后和6个月后,泌尿外科医生和患者完成一份问卷。泌尿外科医生评估了患者与LUTS相关的生活质量的某些方面。国际前列腺症状评分(I-PSS)用于评估LUTS的严重程度,而良性前列腺增生对活动的特异性干扰(BSIA)和总体心理健康率分别评估对日常生活活动和心理健康的影响。
治疗3个月后,与基线相比,坦索罗辛显著改善了平均总I-PSS。6个月后,平均总I-PSS从基线评分20.3分降低了11.0分(降低超过50%)。坦索罗辛还显著改善了平均总BSIA评分和平均总体心理健康率。泌尿外科医生对患者病情的评估证实了这些观察结果:无或轻度排尿和充盈性LUTS的患者增加超过50%,LUTS对日常生活活动无或仅有轻微干扰的患者增加45%。不良反应导致的停药率为2.4%。
本研究表明,在患者和泌尿外科医生看来,坦索罗辛改善了LUTS及其对患者生活质量和日常生活活动的影响。